THE 2025 NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE AND KEY FINDINGS ON THE ROLE OF REGULATORY T CELLS (TREGS)

Ha Tran Thi Hong1,
1 Hệ thống y tế Medlatec

Author contact

Main Article Content

Abstract

Objective: To systemize the historical trajectory, publication trends, molecular mechanisms, and clinical strategies regarding regulatory T cells (Tregs) - a breakthrough achievement honored with the 2025 Nobel Prize in Physiology or Medicine.

Search Methodology and Literature Review: A historical review combined with bibliometrics analysis was conducted. Data were systematically retrieved and synthesized from landmark publications (1990–2026) indexed in PubMed and Scopus databases, utilizing established Medical Subject Headings (MeSH terms: T-Lymphocytes, Regulatory, FOXP3) and free-text keywords (Treg, CAR-Tregs).

Results: The modern era of Treg research was established by the identification of the CD4+CD25+ phenotype (1995) and the master control gene FOXP3 (2001–2003). Publications on Tregs experienced exponential growth after 2003 (~7,000–7,300 papers/year), while the transplantation sector has maintained a steady output of ~2,000 papers/year since 2010. Tregs operate via six distinct mechanisms: cytokine secretion, CD39/CD73 axis, CTLA-4 signaling, tissue adaptation, CNS2 epigenetics, and pTreg induction. Treg deficiency drives autoimmunity and transplant rejection, whereas its accumulation within the tumor microenvironment mediates resistance to immune checkpoint inhibitors. Currently, over 200 clinical trials are exploring Treg-based therapeutics, notably low-dose IL-2 (rezpegaldesleukin), autologous Treg transfer, CDK8/19 inhibition, anti-CCR8, and CAR-Tregs.

Conclusion: The 2025 Nobel Prize marks the dawn of Treg-based precision medicine centered on regulatory T cells. Modulating Treg functions holds transformative potential to reshape the therapeutic landscape of autoimmune diseases, transplants, and oncology.

Article Details